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Recent evidence has reported that proton pump inhibitors (PPIs) can exert antineoplastic
effects through the disruption of pH homeostasis by inhibiting vacuolar ATPase
(H+-VATPase), a proton pump overexpressed in several tumor cells, but this aspect
has not been deeply investigated in EAC yet. In the present study, the expression
of H+-VATPase was assessed through the metaplasia-dysplasia-adenocarcinoma
sequence in Barrett’s esophagus (BE) and the antineoplastic effects of PPIs and cellular
mechanisms involved were evaluated in vitro. H+-VATPase expression was assessed
by immunohistochemistry in paraffined-embedded samples or by immunofluorescence
in cultured BE and EAC cell lines. Cells were treated with different concentrations of
PPIs and parameters of citotoxicity, oxidative stress, and autophagy were evaluated.
H+-VATPase expression was found in all biopsies and cell lines evaluated, showing
differences in the location of the pump between the cell lines. Esomeprazole inhibited
proliferation and cell invasion and induced apoptosis of EAC cells. Production of reactive
oxygen species (ROS) seemed to be involved in the cytotoxic effects observed since
the addition of N-acetylcysteine significantly reduced esomeprazole-induced apoptosis
in EAC cells. Esomeprazole also reduced intracellular pH of tumor cells, whereas only
disturbed the mitochondrial membrane potential in OE33 cells. Esomeprazole induced
autophagy in both EAC cells, but also triggered a blockade in autophagic flux in the
metastatic cell line. These data provide in vitro evidence supporting the potential use of
PPIs as novel antineoplastic drugs for EAC and also shed some light on the mechanisms
that trigger PPIs cytotoxic effects, which differ upon the cell line evaluated.
Keywords: Barrett’s esophagus, esophageal adenocarcinoma, proton pump inhibitors, vacuolar ATPase, reactive
oxygen species
INTRODUCTION
Barrett’s esophagus (BE; El-Serag et al., 2004) is the main risk factor known for developing
esophageal adenocarcinoma (EAC; Tytgat, 1995). The sequence of the carcinogenetic process in
BE is well-known, starting from non-dysplastic BE (ND) to low-grade dysplasia (LGD), high-grade
dysplasia (HGD), and finally invasive EAC (Jankowski et al., 2000). Despite combined therapies,
EAC has poor prognosis with a 5-year survival rate of <20% (Hur et al., 2013), which is why the
research of novel therapeutic strategies remains mandatory.
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Proton pump inhibitors (PPIs) are the most widely used
drugs in the treatment of BE. Their effect is mediated by an
inhibition of the gastric proton pump, increasing the pH in the
stomach and clearly relieving reflux symptoms (Klinkenberg-
Knol et al., 1994). However, growing evidence suggests that
PPIs, besides their role in reducing gastric acid secretion,
may also act as antineoplastic agents targeting the excess acid
production in cancer cells through the inhibition of vacuolar-
ATPases (V-ATPases). Intracellular alkalinization associated with
microenvironment acidification is an important hallmark of
cancer cells and has been related to invasion, metastasis,
proliferation, and resistance to chemotherapy (Raghunand et al.,
2001; Luciani et al., 2004; Rofstad et al., 2006). The reversal of the
aberrant pH gradient in cancer cells has been linked to decreased
tumor growth and inhibition of spontaneous metastases (Robey
et al., 2009).
V-ATPases seem to play a key role in homeostasis of tumor
pH. Thus, increased levels of V-ATPase expression and plasma
cell membrane location have been related to higher metastatic
potential (Sennoune et al., 2004). In addition, several human
tumors have shown to overexpress V-ATPases, especially those
which display multirresistance to cytotoxic drugs (Chow and
Hedley, 1997; Murakami et al., 2001; Luciani et al., 2004; Marino
et al., 2010). For this reason, various studies have exposed the
possibility of using V-ATPases as new targets in cancer treatment
(Marquardt and Center, 1991; Martínez-Zaguilán et al., 1999;
Sennoune et al., 2004; Yeo et al., 2004; Lu et al., 2005; De Milito
et al., 2010).
Given that PPIs are drugs of choice in the treatment of
acid-related diseases and have also shown antineoplastic effects
through their ability to inhibit V-ATPases (Jankowski et al., 2000;
El-Serag et al., 2004) we thought of great interest to elucidate the
potential antineoplastic effects of PPIs on EAC cells.
We therefore conducted an in vitro study to assess whether
the PPI esomeprazole is able to exert antineoplastic effects
on three EAC cell lines, and also the cellular mechanisms
involved in those effects. We evaluated the expression and
subcellular location of V-ATPase in these cell lines, and
the effects of different concentrations of esomeprazole on
proliferation, apoptosis, intracellular pH (pHi), cell invasion,




Esomeprazole magnesium hydrate, omeprazole, N-acetylcysteine
(NAC), thapsigargin (TG), RPMI-1640, MCDB-153 medium,
and antibiotics were from Sigma-Aldrich (Madrid, Spain).
Fetal bovine serum (FBS) and Hank’s balanced salt solution
(HBSS) were both from Life Technologies (Madrid, Spain).
All compounds except pepstatin A, which was dissolved in
100% ethanol and NAC, which was dissolved in culture
media, were dissolved in DMSO and made up with the
media so that the final concentration of the vehicle was not
>0.04% (v/v).
Cell Lines and Culture Conditions
Three EAC cell lines were used in this study. SK-GT-4 cell line
(DMSZ, Braunschweig, Germany) was originally isolated from an
adenocarcinoma of the distal esophagus. OE33 cell line (ECACC,
Salisbury, UK), established from an adenocarcinoma of the lower
esophagus arising in BE and OACM5.1C cells, established from a
lymph node metastasis derived from a primary adenocarcinoma
of distal esophagus with the presence of BE were both purchased
from ECCAC (Salisbury, UK). EAC cells were cultured in RPMI-
1640 supplemented with antibiotics (100 U/mL penicillin, 100
µg/mL streptomycin, and 0.25 µg/mL amphotericin B) and
10% FBS. A non-dysplastic BE derived cell line CP-A (ATCC,
Teddington, USA) was used as a control to evaluate whether
the effects of esomeprazole were specific of tumor cells. CP-A
cells were cultured in MCDB-153 medium supplemented with
0.4 µg/L hydrocortisone (Sigma), 4 mM glutamine (ATCC),
20mg/mL adenine (Sigma-Aldrich), 0.1 pM cholera toxin
(Sigma-Aldrich), 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL
selenium (Sigma), 150 µg/mL BPE (Sciencell), 20 ng/mL EGF
(Sciencell), 100 U/mL penicillin, 100 µg/mL streptomycin, and
0.25µg/mL amphotericin B, and 5% FBS, as previously described
(Peréz-Sayáns et al., 2010).
V-ATPase Staining in the Carcinogenic
Sequence of BE: Immunohistochemistry
Immunohistochemistry was performed in 21 paraffin-embedded
biopsies collected using strict endoscopic and histological
criteria. Archival specimens were obtained from the Pathology
department in Hospital Universitario Miguel Servet (Zaragoza).
Samples were obtained from patients with BE showing
different degrees of dysplasia, according to Riddell’s classification
criteria. Human duodenum samples were included as columnar
epithelium controls.
2.5 µm tissue sections were cut, deparaffinized, rehydrated,
and subjected to epitope retrieval using PT-Link module
(Dako, Barcelona, Spain). The samples were then incubated
with primary antibodies to V-ATPase subunit C1 (Santa Cruz
Biotechnology, Dallas, USA) at 1/50 dilution using an automatic
staining system (Dako Autostainer Plus) and counter-stained
with hematoxylin and eosin. Slides were examined using the
Envision Flex HRP system (Dako) and images were obtained
using LAS EZ software (Leica, Barcelona, Spain) with a Leica DM
2500 microscope.
V-ATPase Expression in Cell Lines by
Confocal Microscopy
To determine the subcellular location of V-ATPase, cells were
double stained targeting both the pump and cell boundaries.
CP-A, OE33, and SK-GT-4 cells were fixed in methanol,
and OACM5.1C cells were fixed in 3% PFA. Cells were
incubated with primary antibody (1:50 Goat polyclonal antibody
against human V-ATPase subunit a, Santa Cruz) in 1% PBS-
BSA followed by incubation with secondary antibody (1:500
Alexa fluor 488, Molecular Probes). Cells’ boundaries were
determined using antibodies against a pool of cytoqueratins
(Dako) in CP-A and SK-GT-4 cells or E-Cadherin (Dako) in
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OE33 cells and subsequently incubated with secondary antibody
(1:1000 Alexa Fluor 546, Molecular Probes). Alternatively, OE33
edges were labeled using Cell Mask plasma membrane stain
(Life Technologies) and OACM5.1C limits were labeled with
Phalloidin Alexa 546 (Molecular Probes).
Cells were mounted in Fluoromount G (Southern Biotech,
Birmingham, USA) + Draq5 (Abcam, Cambridge, UK) and
images were recorded with a confocal laser scanning microscope
(Leica TCS SP2) with a 63x objective.
Apoptosis Assay
The effects of esomeprazole on apoptosis were assessed by flow
cytometry using FACSAria cytometer (BD, Madrid, Spain). Cells
were stained with Annexin V-FITC and propidium iodide (PI).
Apoptotic cells were defined as Annexin V and Annexin V+PI
positive cells. Cells were seeded in 25 cm2 cell culture flasks
and cultured until reaching 40–50% confluence. Then, cells were
treated with esomeprazole (0–200µM under physiological (pH
7.4) or acidic (pH 6.5) conditions for 48 or 24 h, respectively,
and collected for apoptosis determination. The experiments were
repeated four times.
Proliferation Assay
Cell proliferation was measured using a BrdU assay kit (Roche,
Barcelona, Spain) according to the manufacturer’s manual.
Briefly, BE and EAC cells were seeded in 96-well plates and the
next day esomeprazole (0–200 µM) was added in physiological
(pH 7.4) or acidified (pH 6.5) medium. After 48 or 24 h
(physiological or acidified medium, respectively), cells were
labeled with BrdU solution for 4 h and the labeling signal was
quantified by measuring the relative absorbance (A450–A690 nm).
Each assay was done in triplicate and the experiment was
performed at least three times.
Cell Invasion Assay
The effects of esomeprazole on OE33, SK-GT-4, and OACM5.1C
invasiveness were tested using 100,000 cells per well by the
quantitative CytoSelectTM 96-well Cell Invasion Assay (Cell
Biolabs, San Diego, USA) following the manufacturer’s manual.
In brief, cells were seeded in serum-free medium in the upper
chamber of a modified Boyden chamber coated with a uniform
layer of dried membrane matrix solution and allowed to invade
toward 10% FBS for 24 h. Invasive cells that were able to degrade
the matrix proteins in the layer, and ultimately pass through the
pores on the bottom side of the membrane were stained and
quantified as mean relative fluorescence units (RFUs) of repeated
experiments (n = 7) measured at 480/520 nm using the Synergy
HT plate reader (Biotek, Winooski, USA).
Evaluation of Cytosolic pH
pHi was evaluated in OE33, CP-A, and OACM5.1C cells by
flow cytometry using the pH-sensitive fluorescent probe BCECF-
AM (Invitrogen) as previously described (Chung et al., 2011).
Cells were cultured with esomeprazole (0–200 µM) for 24 h.
Then, cells (106 cells/mL) were incubated with 2 µg/mL BCEFC
AM, in PBS for 15 min. pHi was determined by the 525/640
nm fluorescent ratio with a FACSAria cytometer following the
nigericin calibration procedure (Palanca-Wessels et al., 1998).
Evaluation of ROS
The analysis of ROS production was assessed in OE33 and
OACM5.1C cells at different time points after esomeprazole
addition using a quantitative assay (Abcam, Cambridge, UK)
based on ROS-sensitive probe DCFDA. Twenty-five thousand
cells per well were seeded in 96-well plates and the next day,
DCFDA probe and esomeprazole (0–200 µM) were added and
incubated at 37◦C. Intracellular ROS levels were evaluated every
60 min during 6 h and quantified as RFUs with respect to control
cells measured at 495/529 nm using the Synergy HT plate reader
(Biotek). In parallel, in order to evaluate if the addition of the
antioxidant NAC was able to reduce ROS levels, we repeated
the experiment pre-incubating cells with 5 mM NAC for 45 min
before the addition of esomeprazole.
Mitochondrial Membrane Potential (19m)
OE33 and OACM5.1C cells were treated with esomeprazole
(1–200 µM) or vehicle for 24 h. Treatment was removed and
fluorochromes were added for further 30min incubation (2.5µM
Hoechst and TMRM, both fromMolecular Probes). Fluorescence
was visualized using a fluorescence microscope (IX81, Olympus,
Hamburg, Germany). “CellR” software was employed and
the fluorescent signal was quantified using static cytometry
software “ScanR” (Olympus). The fluorescence detection filter
was excitation 540/10 nm, dichroic filter 570 nm and emission
590 nm.
Cytochrome C Quantification
We evaluated the release of cytochrome C to cytosol in the
tumor cell line OE33 using the Cytochrome c Human ELISA
Kit (Abcam) following the manufacturer instructions. Briefly,
cells were treated with esomeprazole (5–200 µM) or the vehicle
for 24 h. Cells and supernatants were collected, washed and
lysed using a soft lysis buffer which dissolves plasma membrane
without affecting intracellular membranes thus allowing the
evaluation of the cytochrome C released from mitochondria.
Absorbance was quantified with a plate reader (Synergy HT) at
450 nm, using 650 nm as a reference wavelength. Each sample was
evaluated in duplicate and the experiment was done three times.
Protein Extracts and Western Blot Analysis
of Autophagy Markers
OE33 and OACM5.1C cells were incubated for 8 and 24 h
with esomeprazole (0–200 µM). For the study of the basal
autophagic flux, cells were cultured for 24 h with esomeprazole
in the presence or absence of 10 µg/mL of the lysosomal
inhibitors E-64d and pepstatin A (Sigma-Aldrich). For the
experiments of autophagy induction, cells were cultured with
esomeprazole in complete RPMI-1640 media or HBSS for 24 h.
Whole-cell protein extracts were obtained by lysing cell pellets
in lysis buffer supplemented with protease inhibitors and protein
content was quantified employing the “BCA Protein Assay
Kit” (Pierce, Thermo Scientific). SDS-PAGE was performed
on acrylamide gels (8–15%) loading 50 µg of proteins per
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lane. Proteins were transferred to nitrocellulose membranes and
incubated in TBS-T with 5% non-fat dry milk. Membranes
were then incubated overnight at 4◦C with primary antibodies:
1:1000 anti-LC3 (Sigma) and 1:1000 anti-p62 (Santa Cruz), and
peroxidase-labeled secondary antibodies: anti-rabbit IgG from
Vector Laboratories (Burlingame, CA, USA) at 1:5000 and anti-
mouse antibody from Dako (Glostrup, Denmark) at 1:2000.
Immunolabeling was detected using SuperSignal WestFemto
(Pierce, Thermo Scientific, Waltham, USA), and visualized with
a luminescent image analyzer (FUJIFILM LAS 3000, Fujifilm,
Barcelona, Spain). MultiGauge software version 3.0 was used for
densitometric analysis.
RNA Extraction and qPCR Analysis of p62
Real time RT-PCR was performed using mRNA of cell cultures
treated with vehicle or esomeprazole (1–200 µM) for 8 and 24
h. Total RNA from EAC cell lines was isolated using RNeasy
Mini Kit (Qiagen, Madrid, Spain) and quantified (NanoDrop
ND-1000, Wilmington, USA). Two micrograms of total RNA
was reverse-transcribed with the Prime Script RT reagent Kit
(Takara, Otsu, Japan). Real-time PCR was performed with
the Prime Script Reagent Kit Perfect Real Time (Takara)
in a thermo cycler LightCycler (Roche Diagnostics). Specific
oligonucleotides for human p62 (5′-ggttgccttttccagtgacg-3′, 5′-
tcgcagacgctacacaagtc-3′) and human β-actin (5′-ggacttcgagcaag
agatgg-3′, 5′-agcactgtgttggcgtacag-3′) expression were used as a
housekeeping gene. The threshold cycle (CT) was determined,
and relative gene expression was expressed as follows: change
in expression (fold) = 2−1(1Ct) where 1Ct = Ct (target)−Ct
(housekeeping), and1(1Ct)=1Ct (treated)−1Ct (control).
Statistical Analyses
Data analysis was performed using SPSS Statistics (IBM, New
York, USA) and Graphpad (GraphPad Software, La Jolla, USA).
Differences between groups were analyzed by student T-test or
by ANOVA as appropriate. Data are expressed as mean± SE.
RESULTS
V-ATPase Is Expressed along the
Carcinogenic Sequence of BE and Also in
BE and EAC Cell Lines, Which Show
Differences in the Location of the Pump
From an overall of 21 biopsies selected, 6 samples were diagnosed
as ND, 4 LGD, 4 HGD, and EAC arising in BE was found in 7
specimens. The results showed that the pump is expressed in all
the stages of neoplastic progression in BE (Figure 1). As shown
in Figure 2, immunofluorescence revealed V-ATPase expression
in all the cell lines evaluated. Barrett’s cell line showed cytosolic
expression of the pump, whereas the non-metastatic tumor
cell lines OE33 and SKGT-4 showed similar staining patterns,
exhibiting prominent cytosolic expression of V-ATPase with
inconspicuous plasma membrane expression. To clarify whether
OE33 cells expressed V-ATPase at plasmamembrane or not, cells’
edges were also labeled using Cell Mask stain. The results showed
again a cellular subpopulation displaying expression of the pump
at plasma membrane.
In contrast, the metastatic cells displayed cytosolic staining
and also an apparent colocalization with phalloidin, suggesting
that in these cells the pump is also located at the cell surface.
Esomeprazole Induced Apoptosis and
Reduced Cell Proliferation of EAC Cells
We first evaluated the proapoptotic effects of omeprazole and
esomeprazole on EAC cells. Since we could observe that both
PPIs significantly increased apoptosis (data not shown) but
esomeprazole displayed a more intense proapoptotic effect than
omeprazole, we decided to use esomeprazole in our experiments.
Given that PPIs are prodrugs which require an acidic pH to
be activated, we evaluated the effects of esomeprazole under
physiological (pH 7.4) or acidified (pH 6.5) medium conditions.
Esomeprazole significantly induced a dose-dependent
increase in apoptosis of OE33 and OACM5.1C cancer cells in all
the culture conditions evaluated, and had no effect on apoptosis
of Barrett’s esophagus cell line (Figure 3).
Since esomeprazole showed a clear induction of apoptosis of
cancer cells without affecting the non-neoplastic cells, we sought
to test the effects of PPI treatment on cell proliferation in EAC
and in BE cell lines. The results observed show that treatment
with esomeprazole significantly inhibited cell proliferation in the
three cell lines evaluated both at physiological and acidic pH
conditions (Figure 4).
Esomeprazole Diminished Cell
Invasiveness of Tumor Cells
We used a fluorometric assay that monitors the ability of
tumor cells to migrate through the membrane basement layer to
evaluate the effect that different concentrations of esomeprazole
(5–200 µM) had on cell invasive properties. The results,
expressed as % of fluorescence of cells treated with vehicle
showed that the highest concentration of esomeprazole (200µM)
significantly reduced the invasive abilities of the three tumor cell
lines (Figure 5): 62.87 ± 3.227% (p = 0.0206); 73.97 ± 5.529%
(p= 0.0274) and 67.29± 5.244% (p= 0.0371) for OE33, SKGT-4
and OACM5.1C, respectively.
Esomeprazole Reduces Intracellular pH of
EAC But Not BE Cells
We evaluated whether treatment with esomeprazole (0–200 µM)
for 24 h was able to induce changes in pHi in CP-A, OE33
and OACM5.1C cells. The analysis of basal pHi indicated that
CP-A cells showed basal pHi-values of 7.59 ± 0.08, OE33 cells
7.82 ± 0.07 and metastatic cells OACM5.1C displayed more
acidic basal pHi-values: 7.09± 0.135 (Figure 6A).
The highest concentration of esomeprazole caused a
significant decrease of pHi in EAC cells OE33 (7.65 ± 0.09
vs. 7.82 ± 0.06 in control cells, p < 0.05) and OACM5.1C
(6.61 ± 0.08 vs. 7.15 ± 0.18, p < 0.05) but had no effect on pHi
of BE cells (Figure 6B).
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FIGURE 1 | Representative images of V-ATPase expression in BE and EAC in biopsy samples. Immunohistochemical labeling of V-ATPase (brown staining) in
paraffin-embedded biopsy samples corresponding to duodenum and the different stages of neoplastic progression in BE and EAC.
FIGURE 2 | Representative images of V-ATPase expression in BE and EAC cell lines. Confocal microscopy showing V-ATPase (green dots) and plasma
membrane (red/orange staining) in BE and EAC cell lines.
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FIGURE 3 | Effects of esomeprazole on apoptosis of EAC and BE cell lines. Apoptosis was evaluated in EAC and BE cell lines under physiological (A) or
acidified (B) conditions. The bars represent the mean % of apoptosis in esomeprazole-treated cells with respect to control cells (DMSO only). All data are expressed
as mean ± SEM of at least three independent experiments. Significant level *p < 0.05; **p < 0.01.
Esomeprazole-Induced Apoptosis Is
Dependent on ROS Production
According to previously published data showing that PPI-
induced cell death is mediated by ROS-dependent mechanisms
in melanoma and lymphoma cells (De Milito et al., 2007; Marino
et al., 2010), we evaluated the implication of ROS production
in the effects triggered by esomeprazole in EAC cells. Firstly,
we observed that the increase in ROS levels is an early event in
EAC cells after the addition of the PPI, which occurs in a dose
and time-dependent manner (Figures 7A,B). We also sought to
assess the role of ROS in esomeprazole-induced apoptosis. In
order to achieve this objective we first checked that preincubation
with the ROS scavenger NAC diminished the levels of ROS
in esomeprazole-treated cells (data not shown). After 48 h of
treatment, esomeprazole induced apoptosis in OE33 cells and
pretreatment with NAC significantly reduced esomeprazole-
induced apoptosis to similar levels than control cells (Figure 7C).
Esomeprazole Diminished 19m in OE33
But Not in OACM5.1C Cells and Had No
Effect On Cytochrome C Release
Mitochondria plays a central role in the regulation of the
apoptotic process. An opening of the mitochondrial permeability
transition pore has been shown to induce depolarization of the
mitochondrial membrane potential (19m) and the release of
pro-apoptotic proteins as cytochrome C (Hengartner, 2000; Ly
et al., 2003). Due that esomeprazole increased ROS production
in EAC cells and mitochondria is one of the main intracellular
targets for oxidative stress we studied whether esomeprazole
affected19m and the release of cytochrome C in EAC cells.
As shown in Figure 8A, the highest concentration of
esomeprazole significantly diminished 19m in OE33 cells
whereas it did not affect 19m in the metastatic cell line
OACM5.1C. Since depolarization of the 19m seems to
be a trigger for the release of proapoptotic proteins from
mitochondria, we therefore evaluated the levels of cytosolic
cytochrome c in OE33 cells. The results shown in Figure 8B
revealed that esomeprazole did not induce the release of
cytochrome c from mitochondria.
Esomeprazole Induces Changes in
Autophagic Activity in EAC Cells
We evaluated by western blot (WB) the levels of the autophagy
markers LC3 and p62 in OE33 and OACM5.1C cells after 8
and 24 h of ESOM treatment. LC3 is detected as two bands
following SDS-PAGE: LC3-I and LC3-II and in conditions of
autophagy activation the amount of LC3-II increases which is
frequently used as an autophagy activation indicator (Mizushima
and Yoshimori, 2007). p62 is used as an indicator of autophagic
flux whose levels decrease when there is an active autophagic
flux within the cell (Moscat and Diaz-Meco, 2009). The results
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FIGURE 4 | Effects of esomeprazole on cell proliferation. Cell proliferation in EAC and BE cell lines at physiological (A) or acidified (B) culture medium. The
results are represented as the percentage of BrdU incorporation in esomeprazole-treated cells in comparison with untreated controls (DMSO only). All data are
expressed as mean ± SEM of at least three independent experiments. Significant level *p < 0.05; **p < 0.01.
FIGURE 5 | Effects of esomeprazole on cell invasion. The effects of esomeprazole on cell invasive properties of EAC cells were expressed as fluorescence values
(RFUs) in esomeprazole-treated cells relative to untreated cells. All data are expressed as mean ± SEM of at least three independent experiments. Significant level
*p < 0.05.
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FIGURE 6 | Intracellular pH. Basal pHi levels of OE33, OACM5.1C and CP-A cells (A). Effects of esomeprazole on pHi (B). Data are represented as the
mean ± SEM of three independent experiments. Significant differences from the respective control values:*p < 0.05.
FIGURE 7 | Esomeprazole and ROS production in EAC cells. ROS levels in esomeprazole-treated OE33 (A) and OACM5.1C (B) cells and effects of the
antioxidant NAC on esomeprazole-induced apoptosis in OE33 cells (C). All data are expressed as the mean ± SEM of at least three independent experiments.
Significant differences: *p < 0.05; **p < 0.01; ***p < 0.001.
showed in Figure 9A revealed that, in OE33 cells, esomeprazole
did not produce changes in neither LC3-II nor p62 levels after 8
h of treatment. However, after 24 h of treatment esomeprazole
increased the levels of both proteins: LC3-II at 200 µM and
p62 at 200 and 50 µM, respectively. In the metastatic cell line
OACM5.1C, esomeprazole led to an increase in the expression of
both proteins after 8 and 24 h of treatment (Figure 9A).
Increased LC3-II levels may be explained by induction of
autophagic activity or due to accumulation of autophagosomes as
a consequence of impaired degradation of autolysosome content.
In addition, accumulation of p62 may be an indicator of a
blockade in the autophagic flux. However, as shown previously,
p62 levels might also be raised as a consequence of increased
p62 transcription induced by ROS (Mathew et al., 2009; Jain
et al., 2010). To clarify whether p62 increased levels were a
consequence of its increased expression, we evaluated the effects
of esomeprazole on p62 gene expression by quantitative RT-PCR.
The results showed that esomeprazole induced an increase in p62
expression in both cell lines after 8 and 24 h (Figure 9B) which
suggests that the increase in p62 levels observed might be due to
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FIGURE 8 | Effects of esomeprazole on mitochondrial membrane potential (A) and cytochrome C release from mitochondria to cytosol (B). Data showed in
(A) are represented as % of TMRM fluorescence intensity in esomeprazole-treated cells with respect to vehicle. Data showed in (B) are expressed as mean ± SEM of
cytosolic concentration of cytochrome c in esomeprazole-treated OE33 cells. All experiments were repeated at least three times. Significant differences from the
respective control values: *p < 0.05.
a rise in mRNA expression rather than as a result of a blockade
of autophagolysosome degradation. To further elucidate this
question, we evaluated basal autophagic flux by assessing the
levels of the autophagic marker LC3-II in the presence or absence
of lysosomal protease inhibitors E-64d and pepstatin A. An
increase in LC3-II levels in the presence of lysosomal inhibitors
is considered an evidence of an efficient autophagic flux, while a
decrease would indicate a failure in the autophagic process which
happened before lysosomal degradation (Barth et al., 2010). The
results showed that esomeprazole effects on autophagic flux are
opposite in the two tumor cell lines. Esomeprazole (200 and
50 µM) significantly increased LC3-II levels in OE33 cells, but
the PPI decreased the levels of the autophagic marker in the
metastatic cell line at the highest concentration (Figure 9C),
which indicates that the PPI blocks basal autophagic flux in
OACM5.1C cells at some point before lysosomal degradation.
Another experimental approach to study basal autophagic flux
consists in evaluating the levels of an autophagy marker after
the induction of autophagy and the subsequent addition of the
treatment with the substance of interest. We induced autophagy
by nutrient deprivation which is achieved by incubation of the
cells in HBSS instead of complete culture medium. The results
showed that in both EAC cell lines, the levels of the autophagic
marker p62 were significantly lower in cells incubated in HBSS,
indicating an effective activation of autophagy (Figure 9C). OE33
and OACM5.1C cells treated with the highest concentration of
esomeprazole displayed a prominent decrease in p62 levels in
comparison to cells treated with vehicle alone, indicating that in
both non-metastatic and metastatic EAC cells esomeprazole did
not produce a blockade in induced autophagy (Figure 9C).
DISCUSSION
V-ATPase plays a key role in tumor pH homeostasis and
PPIs have shown to inhibit this pump (Mattsson et al., 1991;
Mizunashi et al., 1993; Moriyama et al., 1993), thus exerting
antineoplastic effects in different tumors (Marquardt and Center,
1991; Palanca-Wessels et al., 1998; Martínez-Zaguilán et al., 1999;
Luciani et al., 2004; De Milito et al., 2007; Udelnow et al., 2011;
Ishiguro et al., 2012).
It has also been reported that the degree of expression of
this pump increases in parallel with neoplastic transformation in
other tumors (Lu et al., 2005). This is, to our knowledge, the first
study to date evaluating V-ATPase expression along the Barrett’s
carcinogenetic sequence, and the results showed the presence of
the pump in all BE and EAC glands studied, which suggests the
possibility of evaluating this factor as a future therapeutic target
in the treatment of EAC.
To date, several pre-clinical studies have shown that the
administration of PPIs may exert direct cytotoxic effects on
tumor cells by disturbing the H+ transport dynamics and
also may increase the efficacy of anticancer drugs, restoring
chemotherapeutic sensitivity in drug-resistant cancer cells
(Marquardt and Center, 1991; Palanca-Wessels et al., 1998;
Martínez-Zaguilán et al., 1999; Luciani et al., 2004; De Milito
et al., 2007; Udelnow et al., 2011; Ishiguro et al., 2012; Azzarito
et al., 2015; Lugini et al., 2016).
Due the positive results of these studies, we sought of great
interest to evaluate whether PPIs also exerts in vitro antitumor
effects on EAC cells and the cellular mechanisms underlying
these effects, which have not been deeply studied yet. In our study
we decided to evaluate the antineoplastic effects of omeprazole
and esomeprazole, two of the more widely used PPIs in the
treatment of acid-related diseases. Since esomeprazole is a more
potent gastric acid secretion inhibitor than omeprazole and
because we observed that esomeprazole was more effective
inducing apoptosis in our model that omeprazole (data not
shown), we decided to use esomeprazole in our experiments.
First, we assessed if V-ATPase was present in the cell lines used
in our study, which was a requirement for the use of these cells
in our study; and we later evaluated whether the expression was
at plasma membrane level or not. Confocal microscopy results
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FIGURE 9 | Effects on autophagy of EAC cells. OE33 and OACM5.1C cells were used. Autophagy markers LC3 and p62 were evaluated by WB after 8 and 24 h
incubation with esomeprazole (A). p62 relative expression (B) was evaluated by RT-PCR after treatment with esomeprazole for 8 and 24 h and the results are
expressed as the level of expression of p62 with respect to cells treated with vehicle alone. β-actin was used as a housekeeper control. The effects of esomeprazole
on autophagic flux (C) was evaluated by WB after incubating cells in complete media in the presence or absence of lysosomal inhibitors pepstatin A and E-64d, and in
complete media or HBSS for 24 h. WB representative gels are lined up their respective results and all data are represented as the % of expression of autophagy
markers LC3-II or p62 with respect to values obtained in cells treated with vehicle alone. All data are represented as mean ± SEM of three independent experiments.
Significant differences from the respective control values: *p < 0.05; **p < 0.01. Significant differences from the respective treatment in complete medium or medium
without inhibitors: #p < 0.05; ##p < 0.01.
showed that V-ATPase was expressed in all the cell lines studied,
with most of the subcellular populations displaying cytosolic
staining in BE and non-metastatic EAC cell lines. However, the
expression at the plasma membrane seemed to be increased in
the metastatic cell line OACM5.1C, which is in accordance with
previous data obtained in other tumors (Martinez-Zaguilan et al.,
1993).
Proton pump inhibitors are administered as inactive prodrugs
which need low pH to convert in to the active form.
Previous studies have shown that cancer cells can overcome
an acidification of the culture media (Yeo et al., 2004), so we
thought of interest to evaluate whether the in vitro effects of
PPI on cancer cells would be potentiated by low pH culture
medium, conditions. We decided to evaluate apoptosis after
48 h of treatment at physiological pH and after 24 h at acidic
pH based on previous studies with our cell model in which
we observed only a slight increase in apoptosis when apoptotic
inducers were used for <48 h at physiological pH. However,
after 48 h of esomeprazole treatment at acidic pH, most of
the cultures died, indicating that cells could not overcome the
adverse conditions induced by esomeprazole at low pH. These
findings point to higher cytotoxic effects of PPI with lower pH
values, as is the case of tumor surrounding microenvironment,
suggesting the potential clinical applications of PPIs as anticancer
agents.
Our results showed that esomeprazole, especially at high
concentrations (50, 100, and 200 µM) increased apoptosis of
EAC cells without affecting BE cells, which suggests that this
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effect may be exclusive of tumor cells. As seen in other studies
of the antineoplastic action of PPIs, the proapoptotic effects
were observed only when the highest concentration of the
drug was used (Marquardt and Center, 1991; Palanca-Wessels
et al., 1998; Luciani et al., 2004; Yeo et al., 2008; Udelnow
et al., 2011), far from the levels achieved during normal acid
suppression in patients with BE. During normal acid suppression
(20 mg/day), the maximum plasma levels achieved are about 7
µM (Katagiri et al., 2005). However, higher plasma levels can be
achieved in special dosage schedules as is the case of Zollinger-
Ellison syndrome (120–240mg/day; Frucht et al., 1991). In
addition, the drug delivery route can also modify plasma levels of
esomeprazole. Thus, intravenous administration could increase
plasma levels of esomeprazole compared to oral intake (Junghard
et al., 2002). On the other hand, individual plasma levels
achieved after PPI administration should be considered given
that they are extremely variable between subjects. Omeprazole,
esomeprazole, and lansoprazole are extensively metabolized by
CYP2C19 and CYP3A4, and CYP2C19 polymorphisms can
significantly influence the metabolism of PPIs. As a consequence,
some patients could achieve higher levels of the PPI based on
their genotype as higher levels are found in slow metabolizers
(Furuta et al., 2002). In addition, because of the trend of PPIs
to accumulate in tissues displaying low pH-values, it may be
possible to achieve high concentrations of the drug at acidic
compartments—as the tumor site—with the administration of
relatively low doses of PPI. In this context, it would be interesting
to study the tissue concentrations of esomeprazole observed after
the PPI intake to further establish the optimum dosage necessary
in cancer treatment.
The results of the proliferation assays showed that
esomeprazole addition at high concentrations diminished cell
proliferation, which also agrees with the effects of PPIs observed
in other tumors (Marquardt and Center, 1991; Palanca-Wessels
et al., 1998; Luciani et al., 2004; Yeo et al., 2008; Udelnow et al.,
2011). However, we observed that the highest concentrations
of esomeprazole also inhibited proliferation in BE cells too.
Unlike most of the studies performed to date, we included a
non-tumor cell line which corresponds to the precursor lesion
of the tumor, as a control to assess if the effects of the treatments
evaluated were exclusive of EAC cells or not. Barrett’s mucosa
has higher proliferative rate than healthy squamous esophagus
(Mathew et al., 2009), and indeed a reduction in the proliferative
rate in BE cells could represent a benefit in terms of neoplastic
progression because it can reduce the mutation rate and the risk
for neoplastic progression. However, the antiproliferative effects
observed were produced only at 100 and 200 µM, and no effect
was observed at lower concentrations, which are the circulating
levels achieved during a standard acid-suppressive therapy with
PPIs.
The highest concentration of PPI evaluated also showed to
inhibit the invasive properties of EAC cells in a significant
manner. Taken together, the results obtained indicate that PPIs
at high concentrations exert in vitro antineoplastic effects on
EAC cells, which suggests the interest to extend the studies on
this tumor elucidating the cellular mechanisms involved in these
effects. To this respect the few studies existing to date focused
on the mechanisms underlying the antineoplastic effects of PPIs
indicate that they may depend on the cell line evaluated.
One of the mechanisms associated with the antitumor effects
of PPIs previously reported (Martínez-Zaguilán et al., 1999;
Matsuyama et al., 2000) is the reversal of the abnormal pH
gradient existing in cancer cells. The results obtained in our
experiments reflect, on the one hand, the differences existing
between the different cell lines used in this study. Non-metastatic
tumor cells displayed a basal pHi slightly higher than normal
cells, which is in accordance to previous reports (Ouatu-Lascar
and Triadafilopoulos, 1998; Ouatu-Lascar et al., 1999) but
the metastatic cell line showed surprisingly an acidic pHi. A
comparison between pHi of tumor cells with distinct invasive
properties has not been studied yet, but due the potential
implications of pHi in tumor progression it might be interesting
to study this fact in greater depth.
On the other hand, our results showed that esomeprazole
had no significant effects on pHi of BE cells but, as previously
seen in other tumors (De Milito et al., 2007, 2010) the use of
high concentrations of esomeprazole significantly lowered pHi
of cancer cells. Studies in melanoma, gastric cancer, and B-cell
lymphoma showed that PPIs induced an important decrease of
pHi (about 0.5 pH units or higher), thus creating the optimal
conditions for the activation of caspases and different apoptotic
pathways. In our cell model esomeprazole diminished pHi of
tumor cells, but we could observe an important decrease only in
the metastatic cell line OACM5.1C. In contrast, OE33 cells only
showed a slight decrease in intracellular pH upon the addition
of esomeprazole, suggesting that the alteration in pHi might not
be a key mechanism driving the antineoplastic effects of PPIs in
this cell line and reveals again the differences existing between
different EAC cell lines.
An increase in ROS production has also been related to the
antineoplastic effects of PPIs (von Schwarzenberg et al., 2013),
and previous reports showed that PPIs increased ROS production
in melanoma and lymphoma cell lines (Marquardt and Center,
1991; Palanca-Wessels et al., 1998). In our model, esomeprazole
also increased ROS levels in a time and concentration-dependent
manner and ROS seemed to play a key role in the cytotoxic effects
of esomeprazole on EAC cells, since the addition of the ROS
scavenger NAC completely abolished the proapoptotic effects of
esomeprazole. An increase in ROS levels is related to oxidative
stress, and damages mitochondrial membrane thus altering its
9m and allowing the release of proapoptotic molecules to
the cytosol (Cregan et al., 2004). In our model, the highest
concentration of esomeprazole evaluated decreased 19m in
OE33 cells while had no effect on metastatic cells OACM5.1C,
which shows the differences existing between the two EAC cell
lines. Unlike previous reports in melanoma and lymphoma cells
(Marquardt and Center, 1991; Palanca-Wessels et al., 1998), in
EAC cells esomeprazole did not induce the release of cytochrome
C from the mitochondria, which suggests that in our model
PPI-induced apoptosis might be independent from the caspase
activation pathway.
One of the consequences of high levels of ROS is autophagy
induction (Scherz-Shouval et al., 2007). Autophagy is an
adaptative mechanism which contributes to cancer cells survival
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in unfavorable conditions as hypoxia, nutrient starvation, or
cytotoxic agents (Palanca-Wessels et al., 1998; Martínez-Zaguilán
et al., 1999). The role of autophagy in cancer is controversial since
it seems that it could decrease tumorigenesis but also help cancer
cells to overcome the toxicity induced by the antineoplastic
agents (Palanca-Wessels et al., 1998; Martínez-Zaguilán et al.,
1999; Mizushima et al., 2008; White et al., 2010). We evaluated
the effects of esomeprazole in the autophagic markers LC3 and
p62 in EAC cells, and the results showed that esomeprazole
increased both two markers, which may be an indicator of an
activation of autophagy and further blockade of autophagic flux.
However, quantitative RT-PCR revealed that esomeprazole also
increased the expression of p62 in OE33 and OACM5.1C cells,
indicating that the increase in p62 levels seen in WB might be a
consequence of activation at the transcription level rather than
a blockade in autophagic flux. To further elucidate the effects of
esomeprazole on autophagic flux we evaluated basal and induced
autophagy, and the results showed that the effects differ upon the
cell line studied. In the metastatic cells, the results suggest that
esomeprazole blocks basal autophagy and this blockade happens
at some point before autolysosome degradation. These results
agree with the activation and further blockade of autophagic
flux observed previously in pancreatic cancer and melanoma (De
Milito et al., 2007; Udelnow et al., 2011), in whose autophagy
seemed to act as a protective mechanism against the damage
induced by esomeprazole. Of note, esomeprazole did not alter
basal autophagy in non-metastatic cells, which could be a sign of
differences in the mechanisms involved on the cytotoxic effects
of PPIs on EAC cells. On the other hand, once autophagy was
induced by HBSS, esomeprazole diminished p62 levels with
respect to control cells in both EAC cell lines, indicating that the
PPI did not block induced autophagic flux neither in OE33 nor in
OACM5.1C cells. The results of the evaluation of autophagy are
very interesting and reveal again the differences existing between
the two EAC cells evaluated. While the activation of autophagy
and further blockade of autophagic flux induced by PPI shown
in the metastatic cells agree with previous reports observed in
melanoma and pancreatic adenocarcinoma (De Milito et al.,
2007; Udelnow et al., 2011), esomeprazole did not block basal
autophagy in the non-metastatic cell line, suggesting that the role
of autophagy in the cytotoxicity induced by PPIs may be different
depending on the cell line evaluated.
In conclusion, the present study demonstrates that PPI exerts
antineoplastic effects on EAC in vitro. PPIs induced a decrease
in pHi of EAC cells and an increase in ROS levels, which is
responsible of the proapoptotic effects observed. However, the
cellular mechanisms involved in those effects seem to vary upon
the cell line evaluated. Our study suggests that mechanisms
involved in ROS production and regulation of pHi may be
relevant targets for new antitumor strategies and points to the
possibility to use PPIs as antineoplastic drugs against esophageal
adenocarcinoma.
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